全文获取类型
收费全文 | 109339篇 |
免费 | 8495篇 |
国内免费 | 4250篇 |
专业分类
耳鼻咽喉 | 586篇 |
儿科学 | 2103篇 |
妇产科学 | 1361篇 |
基础医学 | 15511篇 |
口腔科学 | 1380篇 |
临床医学 | 7913篇 |
内科学 | 19253篇 |
皮肤病学 | 1967篇 |
神经病学 | 8566篇 |
特种医学 | 1404篇 |
外国民族医学 | 22篇 |
外科学 | 7856篇 |
综合类 | 11868篇 |
现状与发展 | 28篇 |
预防医学 | 6457篇 |
眼科学 | 1583篇 |
药学 | 20153篇 |
20篇 | |
中国医学 | 4355篇 |
肿瘤学 | 9698篇 |
出版年
2024年 | 247篇 |
2023年 | 1697篇 |
2022年 | 2911篇 |
2021年 | 3967篇 |
2020年 | 3451篇 |
2019年 | 3880篇 |
2018年 | 3864篇 |
2017年 | 3571篇 |
2016年 | 3481篇 |
2015年 | 3946篇 |
2014年 | 6203篇 |
2013年 | 8121篇 |
2012年 | 6146篇 |
2011年 | 7267篇 |
2010年 | 5931篇 |
2009年 | 5466篇 |
2008年 | 5492篇 |
2007年 | 5010篇 |
2006年 | 4523篇 |
2005年 | 3962篇 |
2004年 | 3434篇 |
2003年 | 3008篇 |
2002年 | 2497篇 |
2001年 | 2074篇 |
2000年 | 1662篇 |
1999年 | 1571篇 |
1998年 | 1359篇 |
1997年 | 1275篇 |
1996年 | 1053篇 |
1995年 | 966篇 |
1994年 | 831篇 |
1993年 | 766篇 |
1992年 | 639篇 |
1991年 | 623篇 |
1990年 | 581篇 |
1989年 | 475篇 |
1988年 | 439篇 |
1987年 | 317篇 |
1986年 | 320篇 |
1985年 | 1038篇 |
1984年 | 1230篇 |
1983年 | 944篇 |
1982年 | 1064篇 |
1981年 | 1014篇 |
1980年 | 760篇 |
1979年 | 697篇 |
1978年 | 510篇 |
1977年 | 418篇 |
1976年 | 454篇 |
1975年 | 342篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
2.
3.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components. 相似文献
4.
内生菌由细菌、真菌、古菌和原生生物组成,它们生活在植物的活体组织中,具有丰富的次级代谢产物多样性。人参内生菌在人参的生长发育、次级代谢产物的生成和环境适应等方面均有重要的促进作用,对人参的产量和品质有较大影响。随着人们在微生物领域研究的深入,高通量测序技术已经成为研究植物内生菌的重要方法。文章主要从人参内生菌分离与鉴定研究方法、人参内生菌的多样性、人参内生菌及其次级代谢产物的活性、人参内生菌对宿主的影响等4个方面对人参内生菌近年来的研究进展进行讨论,并对其发展方向提出展望,以期为药用植物内生菌研究和品质改良提供新思路、新方法。 相似文献
5.
6.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
7.
8.
《Cancer cell》2021,39(9):1214-1226.e10
- Download : Download high-res image (204KB)
- Download : Download full-size image
9.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献